Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Du, Shunda; Wisskirchen, Karin; Zhang, Ke; Protzer, Ulrike

doi:2025.31.1.e44

Clin Mol Hepatol > Volume 31(1); 2025 > Article

Correspondence

Clinical and Molecular Hepatology 2025;31(1): e44-e47.
doi: https://doi.org/10.3350/cmh.2024.0781

Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du¹

, Karin Wisskirchen², Ke Zhang², Ulrike Protzer³

¹Department of Liver Surgery, Peking Union Medical College Hospital, PUMC, and Chinese Academy of Medical Sciences, Beijing, P. R. China
²SCG Cell Therapy Pte. Ltd., Singapore, Singapore
³Institute of Virology, School of Medicine, Technical University of Munich / Helmholtz Munich, Munich, Germany

Correspondence :

Shunda Du ,
Tel: +86-10-69152836, Fax: +86-10-69156043, Email: dushd@pumch.cn
Ulrike Protzer ,
Tel: +49-89-4140-6821, Fax: +49-89-4140-6823, Email: protzer@tum.de

Received: September 23, 2024 Revised: October 12, 2024 Accepted: October 20, 2024

KeyWords: Hepatitis B virus; T cell therapy; RNA electroporation; lentivirus transduction; Hepatocellular carcinoma